YD Bio Limited's U.S. affiliate, EG BioMed US, has secured clinical lab licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified, CAP-accredited lab's footprint to 46 states plus D.C. and Guam. This expansion enhances patient access to DNA methylation-based early cancer detection tests for various cancers, supporting YD Bio's strategy to build a platform based on real-world molecular data. The company views this growth as key to accelerating data collection and commercial validation of its cancer detection technology. A planned merger with EG BioMed remains pending regulatory approvals and final agreements.
LKQ Corporation announced it will publish its financial results for the second quarter of 2026 on July 30. The company will host a conference call and webcast with senior management to discuss the results, providing investors an opportunity to hear i...
First Federal Savings Bank and the Independent Community Bankers of America (ICBA) have issued 10 financial safety tips to help travelers manage their money securely during the summer travel season. Key advice includes notifying banks of travel plans...
Vivani Medical's wholly owned subsidiary Cortigent will merge with Nasdaq-listed ClearOne, which will be renamed Cortigent Holdings and trade under the ticker CRGT. Vivani will own a majority stake in the combined company, which will focus on advanci...
Diffusion, a global communications agency, is growing its home and interiors portfolio by signing new clients including POVISON (furniture), LUSA Lighting, and Induction Hardware (appliances). The agency will support these premium brands with integra...
Heathrow Finance PLC announced a €350 million offering of 4-year senior secured notes with a stabilization period starting July 2, 2026, and ending by August 7, 2026. BNP Paribas and other major banks will manage the stabilization to support the bond...
